Pulse Biosciences, Inc. (PLSE)
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.
PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data
Pulse Biosciences shares late-breaking AF data showing up to 100% procedural success, fast procedures and low adverse events for nPulse.
Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
PLSE has secured FDA IDE approval to launch its nPulse AF ablation study.
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.
Pulse Biosciences, Inc. (PLSE) Q3 2025 Earnings Call Transcript
Pulse Biosciences, Inc. ( PLSE ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul LaViolette - President, CEO & Co-Chairman of the Board Jon Skinner - Chief Financial Officer Conference Call Participants Philip Taylor - Gilmartin Group LLC Suraj Kalia - Oppenheimer & Co. Inc., Research Division Presentation Operator Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today.
Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.16 per share a year ago.
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q1 2025 Earnings Call May 8, 2025 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Jon Skinner – CFO Paul LaViolette – CEO and Co-Chairman of the Board Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences First Quarter 2025 Financial Results Conference Call. At this time all lines are in listen-only mode.
Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of the Board of Directors Jon Skinner - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Louella, and I will be your conference operator today.
Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations Burke Barrett - President & Chief Executive Officer Mike Koffler - Vice President, Finance Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
